Therapeutic agents such as atezolizumab, avelumab, and durvalumab effectively disrupt this interaction, as PD-L1 binding to PD-1 on T cells suppresses T-cell activity and facilitates immune escape by tumor cells, as depicted in Figure 1 [13]. This evidence concerns the gene PDCD1 and neoplasm.